Pillar Biosciences Launches oncoReveal® Myeloid v2 Panel, Expanding to 80 Genes and Advancing Detection of Long and Multiple FLT3-ITDs

NATICK, Mass., Oct. 5, 2026 /PRNewswire/ -- Pillar Biosciences today announced the launch of the oncoReveal® Myeloid v2 Panel, an expanded research-use-only (RUO) DNA next-generation sequencing (NGS) panel for myeloid malignancies. The panel expands the original oncoReveal Myeloid Panel from 58 to 80 gene targets and enhances detection of FLT3 internal tandem duplications (ITDs), including long and multiple ITDs that can be challenging for NGS assays.

Building on the original 58-gene panel, oncoReveal Myeloid v2 adds 22 genes while retaining all prior content, giving laboratories broader, guideline-relevant coverage without disrupting existing workflows. Only 4 out of the original 766 amplicons covering the original 58 genes are changed to accommodate the expansion — a result of Pillar's proprietary SLIMamp® chemistry and VersaTile™ primer design tool, which together enable efficient panel scaling while preserving the validated performance of existing content. The full updated gene list will be available on pillarbiosci.com at launch.

"With oncoReveal Myeloid v2, we significantly expanded our myeloid gene content while preserving the trusted panel content laboratories already rely on," said ShiPing Zou, Senior Director, Product Management at Pillar Biosciences. "We also invested significant effort in FLT3-ITD detection so laboratories can obtain accurate, base-pair-resolved calls for long and multiple ITDs without defaulting to a separate fragment-analysis workflow."

A key advancement in oncoReveal Myeloid v2 is the ability to accurately detect long (300+ bp) and multiple FLT3 internal tandem duplications (ITDs) with 2 x 150 sequencing, a variant class that has historically challenged short-read NGS:

Why FLT3-ITDs are challenging

• FLT3-ITDs occur in an estimated 20–30% of de novo AML cases and are associated with poor prognosis, making accurate detection important to the profiling of heme malignancies.
• ITDs can range from a few base pairs to more than 400 bp. Their repetitive sequence content can make it difficult for short-read NGS panels to detect and size accurately, particularly longer ITDs.
• Laboratories have therefore historically relied on capillary electrophoresis (CE) fragment analysis to confirm FLT3-ITD status and calculate allelic ratio (AR), adding time and complexity.

Performance with long and multiple ITDs

• In an independent evaluation of 111 myeloid/MPN samples, including 23 FLT3-ITD-positive samples with ITDs from 12 bp to 279 bp, the oncoReveal Myeloid v2 Panel and PiVAT® informatics accurately detected and sized ITDs using standard 2x150 bp short-read sequencing. This included ITDs up to 279 bp and 9 samples with 2–4 concurrent ITDs.
• Detection of long and multiple ITDs in a single NGS run can identify distinct clonal populations, each with its own ITD length and variant allele frequency (VAF), within the same sample—detail that a single CE-based allelic ratio can obscure.
• NGS-derived VAFs trended consistently with allelic ratios from orthogonal CE-based fragment analysis across evaluated ITD lengths, supporting confidence in the NGS-based calls.
• FLT3-ITDs were detected to ≤1% VAF, providing researchers with a sensitive, single-workflow alternative to routing FLT3-suspected samples to separate fragment analysis.

About Pillar Biosciences
Pillar Biosciences is a global provider of next-generation sequencing (NGS) kitted solutions designed to deliver high analytical performance and operational efficiency for cancer testing. Powered by proprietary SLIMamp® and PiVAT® technologies, Pillar enables localized testing to expand access to complex molecular diagnostics worldwide. The company offers a growing portfolio of IVD and RUO NGS kits for tumor profiling, biomarker analysis, and molecular research and monitoring applications. For more information, visit pillarbiosci.com and connect with us on LinkedIn.

SOURCE Pillar Biosciences, Inc.